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Abstract 
Lupus is an autoimmune disease that pri-
marily affects young women of childbearing
age. Fertility rates in lupus patients depend on
various factors, including disease activity,
nephritis, and the presence of antiphospho-
lipid antibodies; however, after lupus patients
become pregnant, different factors may affect
the course of pregnancy, such as the produc-
tion of autoantibodies, pre-existing renal dis-
ease, and eclampsia, among others. The pla-
centa is a temporary hemochorial organ that
prevents immunological conflict due to expo-
sure to alloantigens at the maternal-fetal inter-
face; placental regulatory T cells play a major
role in maternal-fetal tolerance. Typically, sig-
nificant amounts of maternal IgG class anti-
bodies cross the placenta and enter the fetal
circulation. This transition depends on the dis-
tribution of Fc receptors along the syncytiotro-
phoblast. The production of antinuclear anti-
bodies (ANA) is a hallmark of lupus, and these
autoantibodies can form immune complexes
that are typically trapped in the placenta dur-
ing gestation. However, the entry of ANA into
the fetal circulation depends on the IgG-ANA
concentration and the FcR placental density.
Maternal antinuclear antibodies with anti-Ro
or anti-La specificity might be pathogenic to
the fetus if transfused by the placental path-
way and could induce neonatal pathologies,
such as neonatal lupus and congenital heart
block. Here, we review the experimental and
clinical data supporting a pathogenic role for
maternal autoantibodies transmitted to the
fetus. 
Introduction
Although Malcolm Hargraves defined lupus
erythematosus (LE) factor in 1948, the specific
autoantibodies and autoreactive lymphocytes
in systemic lupus erythematosus (SLE)
patients were not described for two decades.
The discovery of these molecules indicated the
autoimmune nature of this disease.1 The
prevalence of SLE is approximately 20-150
cases per 100,000 individuals, and the clinical
manifestations of this disease result from the
failure of immune tolerance mechanisms,
resulting in autoimmunity and tissue damage
and leading to internal organ dysfunction.2 The
complex pathophysiological mechanisms of
SLE include predisposing MHC genes, epige-
netic factors that modulate the transcription of
cytokines involved in tissue damage, environ-
mental factors such as UV light, or infectious
agents. Sexual hormones, including estrogens
or prolactins, are also important, and SLE pri-
marily affects young women. Taken together,
these factors and the breakdown of immuno-
logical tolerance facilitate disease expression.
Lupus primarily affects women of childbearing
age, and studies of fertility rates in lupus
patients have yielded conflicting results.
Cyclophosphamide therapy, anti-phospholipid
antibody and/or anti-β-2-microglobulin pro-
duction, and pre-existing lupus nephritis have
been associated with decreased fertility.3
The prevalence of pre-eclampsia during
pregnancy may be higher in lupus patients,
and high blood pressure, pre-existing nephri-
tis, and the presence of anti-phospholipid anti-
bodies may worsen the prognosis for a healthy
pregnancy.3-5
Placenta
The placenta is a temporary hemochorial
organ that penetrates the endometrium and
develops upon implantation of the blastocyst
and is removed at birth. Placental circulatory
systems include i) the umbilical cord, ii) the
systemic circulatory system and iii) the yolk
system. The expression of Hox genes in the
allantoic layer is necessary for the functional
development of the placenta; these genes are
essential for extra-embryonic placental func-
tion and embryo survival. For example, the
intervention of Hox is critical for expansion of
the placentary vasculature.6 In addition to the
vasculature, the placenta is composed of tro-
phoblastic cells derived from the ectoderm,
cells originating from the inner cell mass and
epiblast (amnion), and minor cell components
from the maternal blood. The amnion is an
epithelial cell layer that lies on the surface of
the basement membrane, and the chorion is
juxtaposed to connective tissue associated
with chorionic villi and fetal vessels, which are
interdigitated with the chorionic decidua and
maternal vessels. The placental villous
parenchyma comprises 30 to 60 villi, the func-
tional units that facilitate the diffusion and
active transport of nutrients and remove meta-
bolic and cellular wastes from the fetal circula-
tion. On the maternal side, the parenchymal
villi consist of a thin basal layer corresponding
to the maternal-fetal interface that comprises
trophoblast and fibrinoid materials, endome-
trial stromal fibroblast-like cells, macrophages,
arteries, and veins. The umbilical cord and
chorion tissue originate from the mesoderm,
and the cord is derived from the amniotic
epithelium and two arteries and one vein
embedded in the Wharton gelatin.7
Tolerance and placenta
The placenta has evolved protective mecha-
nisms to tolerate the maternal immune system
and prevent immunological conflict through
constant exposure to alloantigens.8 Placental
regulatory T cells (Tregs) play a major role in
tolerance at the maternal-fetal interface.9
Tregs belong to a CD4+ T cell subset that
express the Foxp3 transcription factor; indeed,
the congenital or acquired deficiency of Foxp3
results in autoimmunity. There are two path-
ways for Treg differentiation: the thymic path-
way (tTreg) and the peripheral pathway
(pTreg). In placental mammals, the expression
of Foxp3 outside the thymus depends on the
CNS1 enhancer, which binds Smad3 and RAR
(retinoic acid receptor) and induces TGF-β-
dependent Foxp3 expression.9,10 CNS1 is a
retrotransposon belonging to the SINE MIR
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family of retrotransposons. These transposable
elements appeared evolutionarily in the
Mesozoic era, and CNS1 was amplified in a
radiated manner in placental mammals, mar-
supials, and monotrems.11 CNS1 deficiency in
pregnant mice increases fetal resorption, sug-
gesting that during evolution, the CNS1
sequence was generated as a mechanism to
strengthen maternal-fetal tolerance.9
Physiological transit 
of maternal immunoglobulin G 
The placental transfer of maternal IgG to the
fetus is a physiological fetal protection mecha-
nism that extends through the newborn stage.
This protective mechanism is important
because the adaptive immune system of the
newborn is not exposed to environmental anti-
gens before birth. Among the maternal
immunoglobulins, IgG is a unique antibody
class that crosses the placenta in significant
amounts, and the physiological transit of
maternal IgG into the fetus depends on Fc
receptor expression in the syncytiotrophoblast
(FcyRI, FcyRII, FcgRIIIa, FcRn, and FcgRIIIb).
For example, in the full-term placenta, FcyRI
and FcyRII receptors are predominantly
expressed on endothelial and Hofbauer cells,
whereas FcgRIIIa, FcgRIIIb, and FcRn are wide-
ly distributed along trophoblasts;12 thus, the
passive transfer of maternal antibodies
depends on the IgG level and the isotype/FcR
ratio. Other miscellaneous factors, such as the
integrity of the placenta as a physical barrier,
might influence IgG passage (Figure 1).13
Antinuclear antibody 
immune-complex deposition 
in lupus placenta 
In lupus, autoantibody production against a
wide variety of intracellular antigens reflects
the autoantigen-mediated polyclonal activa-
tion of B cells. Antinuclear antibodies (ANAs)
could form immune complexes (IC) in situ that
are captured by the placenta during pregnancy,
thereby preventing the transfer of maternal
ANAs to the fetus. Thus, the placental tissue
functions as an immunosorbent that traps
ANA-ICs in the trophoblast and amnios.14
Subsequently, the ICs could activate the classic
complement pathway; C3 and C1q fragments
have been frequently observed in the tro-
phoblast, suggesting decreased C3 and C4 lev-
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Figure 1. Physiological and pathologic IgG transit through placenta. 1) Normally the maternal IgG may cross the placental barrier. 2)
Placental IgG transcytosis occurs via Fc receptors (FcR). 3) Maternal IgG must cross the syncytiotrophoblast and reach the fetal vas-
cular endothelium. 4) After FcR deliver its cargo, the receptor is recycled to form new IgG/FcR complexes. 5) SLE immune complexes
(IC) can be trapped in placenta that function as an immunosorbent, IC trapping by FcγRIIIa induces transduction signals that increase
intracellular Ca2+, inositol-1,4,5-triphosphate, and phosphatidylinositol (IP4) levels, which promote the activation of IFN-g and TNF,










els in maternal serum, in association with pla-
cental dysfunction.15 In addition, IC trapping
through Fc RIIIa transduces signals that
increase intracellular Ca2+, inositol-1,4,5-
triphosphate, and phosphatidylinositol (IP4)
levels, promoting the activation of IFN-g and
TNF, which subsequently activate NK cells for
antibody dependent cell mediated cytotoxicity
(ADCC) cell-mediated reactions leading to vel-
litis and deciduitis, as commonly observed in
the placentas of lupus patients (Figure 1).13,16,17
Transplacental transit 
of maternal antinuclear 
antibodies
In 1954, Bridge and Foley described the pas-
sive transfer of maternal ANA to the fetus.
Indeed, these authors reported the placental
transfer of LE factor into newborns apparently
without clinical consequences,18 and this find-
ing has been confirmed by multiple reports.19-22
Nathan and Snapper were the first clinicians
to describe a potential role for maternal lupus
autoantibodies in neonates in a reported case
of neonatal thrombocytopenia associated with
maternal LE factor.21 These observations
reflected a natural experiment induced by
transplacental transit of maternal autoantibod-
ies. Subsequently, different experimental
approaches in rodents have been used to
assess the placentary kinetics of ANA (anti-
DNA, Sm, RNP, La, and anti-Ro), revealing that
i) the entry of ANA into the fetus depends on
the antibody concentration and FcR placental
density; and ii) the transferred ANA is deposit-
ed into fetal tissues in a dose-dependent man-
ner.23
Neonatal pathology induced by
maternal autoantibodies
In 1954, McCuistion and Schoch described
skin lesions in neonates associated with
maternal ANA transfer. The authors reported
the case of a newborn with discoid lupus
whose mother had LE skin lesions, suggesting
that the etiological agent was transmitted into
the fetus through the placental pathway.24
However, this hypothesis was only proved 27
years later in 1981, when Thomas Provost et al.
demonstrated that maternal anti-Ro antibodies
caused neonatal lupus (NL), which was subse-
quently confirmed by William Weston et al.25-27
In 1977, Chameides contributed to the cur-
rent understanding of the multiorganic spec-
trum of NL when he described congenital heart
block (CHB) in newborns of mothers with SLE.
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Figure 2. The pathologic mechanisms of CHB induced by maternal anti-Ro/La antibodies. Anti-Ro 52 bind fetal 5-HT4A because Ro52
possesses two sequences (residues 365-382 and 380-396) that share partial homology with the 5-HT4A serotonin receptor. This recep-
tor is widely expressed in the atrial tissue of fetal heart. Maternal anti-Ro antibodies may therefore exert their pathogenic activity by










After observing fibrotic changes in the atri-
oventricular node during the autopsy of a new-
born that died from CHB, this author suggest-
ed that these changes influenced this patholo-
gy, and the early development of this nodal
fibrosis presumably contributed to the
observed CHB.28 With or without the develop-
ment of CHB, NL is a rare disease that typically
depends on the expression of maternal anti-
Ro/La antibodies.29 A few studies have reported
anti-RNP specificity, but this association lacks
experimental confirmation. 
Ro/SSA molecular complex 
Antibodies to Ro/SSA antigens are serological
markers of Sjögren’s syndrome and some fea-
tures of LE, such as subacute cutaneous lupus
erythematosus (SCLE). Anti-Ro antibodies were
discovered by Clark et al.30 and were then used
as molecular probes to determine that the Ro
complex includes the Ro60 ribonucleoprotein.
Ro60 displays a donut-shaped form and associ-
ates with small cytoplasmic Y RNAs.
Interestingly, Ro60, which is expressed in the
nucleus and cytoplasm of lymphoid cells, also
binds to RNAs that are incorrectly edited and
cannot be translated. Ro60 has also been impli-
cated in 5S rRNA editing and in the regulation of
micro (mi) RNA biogenesis and RNA deriva-
tives.31-37 Ro52 is another component of the Ro
complex. Interestingly, this ribonucleoprotein
contains zinc finger domains and a leucine zip-
per. Ro52 is encoded by a different gene than
Ro60 and has different features and functions,
such as binding to various DNA and RNA mole-
cules.38,39 Ro52 possesses two sequences at the
carboxyl terminus (residues 365-382 and 380-
396) that share partial homology with the 5-
HT4A serotonin receptor.40 These receptors are
involved in cardiovascular stimulation and con-
sequently participate in arrhythmias; therefore,
5-HT4A receptors are widely expressed in the
atrial tissue of fetal hearts.41 These molecular
data are of clinical importance for understand-
ing the pathophysiology of CHB. Another compo-
nent of the Ro complex is the erythrocyte-
derived Ro54 protein, which is not relevant in NL
syndromes. La/SSA is a 48-kDa ribonucleopro-
tein that forms a complex with Ro60 through a
small YRNA. The La antigen participates in RNA
maturation as a transcription termination factor
of RNA polymerase III.31,32
Clinical spectrum of neonatal
diseases induced by maternal
antinuclear antibodies 
Different neonatal pathologies are induced
by maternal ANAs, including NL with or with-
out CHB. Other cases of NL might develop
hepatobiliar involvement and/or hematologic
symptoms such as cytopenias.
The skin manifestations of NL appear at
birth or within a few weeks after birth, and
these conditions might persist for 16 weeks.42
Primary cutaneous lesions are erythematous
papules distributed on the face and scalp, but
sometimes the plaques are scattered.
Newborns exhibit periorbital erythema,
referred to as owl eyes, and these babies might
display polycyclic lesions mimicking those
observed in SCLE. At the onset or during exac-
erbation, the appearance of erythematous
lesions is independent of photo exposure.
Other less common skin lesions include
petechiae, telangiectasia and cutis
marmorata.29,43 Erythematous lesions eventu-
ally produce residual depigmentation and atro-
phy. The histopathology of these neonate skin
conditions shows lesions mimicking SCLE or
neutrophilic dermatitis, accompanied with
mononuclear cell infiltration into the perivas-
cular and periadnexal dermis and vacuolar
degeneration of the basal cell layer.44,45 Lela
Lee et al. extensively examined the pathophys-
iology of cutaneous NL using human foreskin
grafted onto nude mice to assess the effect of
human anti-Ro antibodies.46 These experi-
ments demonstrated the pathogenic effects of
anti-Ro antibodies, suggesting that antibody
deposition induces ADCC cytotoxicity, leading
to the inflammation and apoptosis of ker-
atinocytes, which release intracellular Ro anti-
gens, creating a pathophysiological loop.47,48
The cardiac manifestations of NL include
variable degrees of CHB, which is manifested
as intrauterine bradycardia or low heart rates
at birth. These anomalies persist for days or
months, depending on the extent of the block-
ade, and when fibrosis of the atrial node is
present, the blockage is permanent. In first-
degree atrioventricular block (AVB), the car-
diac rate normalization is correlated with
maternal autoantibody elimination from
neonate circulation. Nevertheless, in third-
degree AVB, the permanent damage in the
neonatal conduction system might require a
pacemaker. CHB is a rare disease, affecting 1
in 20,000 live births, and in most cases, CHB
results from inflammation of the AV node,
which impedes the normal conduction of the
electrical impulse to the ventricle. CHB can be
associated with mesothelioma or structural
cardiac abnormalities, such as isomerism or
atrioventricular canal defects, but in 90% of
cases, CHB reflects the transfer of maternal
anti-Ro/La antibodies.49 The association of
anti-Ro antibodies with CHB is highly specific,
as the prevalence of anti-Ro in pregnant
women is low, ranging from 0.8 to 1% in
Caucasians50,51 and 0.2% in Latin-American
mestizo.52 The presence of anti-Ro/La antibod-
ies in pregnant women has been associated
with low fetal heart rate, suggesting the possi-
bility of CHB, and this suspicion must be doc-
umented using a fetal echocardiogram. In
2003, Brucato et al. proposed the following cri-
teria to determine whether an atrioventricular
block is congenital: i) the blockage must be
diagnosed in utero; and ii) when bradycardia
is detected after birth, the diagnosis should be
made during the first 27 days.53 Newborns with
CHB might have sinus bradycardia with abnor-
mal QT space, as determined by electrocardio-
graphy.54
In the 2.8% of pregnant women with anti-
Ro/La antibodies, these antibodies might
induce neonatal disease, and 3 to 15% of these
babies will develop CHB. In the fetus, abnor-
mal conduction must be antenatally assessed
through Doppler sonography or noninvasive
fetal electrocardiography, as both techniques
yield good correlations, although noninvasive
fetal electrocardiography shows greater speci-
ficity and sensitivity.55 In neonates with CHB,
the outcome rarely results in dilated cardiomy-
opathy; however, this complication might
occur regardless of pacemaker application, as
these babies develop progressive heart failure
after 11.6 months. Fortunately, few cases
develop progressive deterioration and fatal
ventricular failure, although some of these
cases require heart transplantation.56,57 In
1957, Hogg described endocardial fibroelasto-
sis as another cardiac manifestation of NL.58
This pathology primarily affects the left ventri-
cle and causes severe ventricular dysfunction.
This fibroelastosis has not been definitively
associated with AVB, and neonates with this
condition may develop skin manifestations as
early as 1 month after birth.57 Congenital struc-
tural abnormalities have also been associated
with the presence of maternal autoantibodies,
although this association is incidental rather
than causative.57
Experimental models for understanding the
pathophysiology of CHB have been developed
by different groups. The Buyon lab demonstrat-
ed toxic effects of maternal anti-Ro/La antibod-
ies on the fetal cardiac conduction system.
Using pregnant female Balb/c mice immunized
with recombinant antigens, these researchers
demonstrated that the offspring display CHB.
Approximately 20% of the neonatal animals
developed first-degree AVB after immunization
with Ro60, and 7% of the neonatal animals
developed first-degree AVB after immunization
with the La/SSB antigen. Interestingly, ani-
mals immunized with the Ro52 alpha isoform
developed Mobitz I AVB, while immunization
with the beta isoform induced complete AVB.59
Clinical and experimental data have clearly
demonstrated that anti-Ro antibodies induce
CHB. However, because the Ro complex is
intracellular, it was unclear how the maternal
antibodies targeted the fetal intracellular anti-
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gen. Using an in vitro system, Jill Buyon et al.
demonstrated that Ro or La antigens were
translocated to the cardiomyocyte cell surface
through apoptotic membranes. Thus, the phys-
iological programmed cell death observed dur-
ing heart development favors the antigenic tar-
geting of Ro/La antigens by maternal autoanti-
bodies. Through this mechanism, autoanti-
gens are externalized during apoptosis,60,61 and
anti-Ro/La antibodies subsequently reach their
target, releasing cytokines, such as TNF and
TGF-β, that induce cardiomyocyte inflamma-
tion. In addition, TGF-β induces the trans-dif-
ferentiation of cardiac fibroblasts, leading to
fibrosis and AV node scaring,62 and stimulates
the plasminogen activator receptor, which
feeds the fibrotic process.63 The toxic effect of
anti-Ro52 antibodies on the conduction system
is dose-dependent. Studies have demonstrated
that these antibodies alter cardiomyocyte cal-
cium homeostasis. Notably, Ro52 epitopes dif-
fer in each species.64-66 The sequences critical
for CHB induction in humans have been
deduced, but for ethical reasons, the effects of
mutations have not been examined in vivo.
Anti-Ro antibodies decouple the excitation-
contraction cycles of the Cav1.3 subunit of L-
type calcium channels, producing contractile
dysfunction.67,68 Cav1.3 knockout transgenic
mice develop first-degree AVB, and the block-
age increases after immunization with Ro or
La antigens (Figure 2).69 To understand the
evolution of CHB, we must consider the
ontogeny of the Ro (Figure 2) complex, which
is detected at 12 weeks of development.70 The
beta transcript of Ro52 is generated through
alternative splicing and is fully expressed in
the fetal heart at 14 weeks of development.
Chan et al. showed that the expression of the
beta transcript declines after birth and is
replaced with the alpha transcript, characteris-
tic of the adult heart.71 Thus, considering the
fate of the alpha transcript of Ro52, the risk for
CHB increases from 18 to 24 weeks of develop-
ment.72 Clinically, CHB has two stages: the first
stage occurs from 18 to 24 weeks and is char-
acterized by a normal fetal heart rate; the sec-
ond stage, which is characterized by bradycar-
dia, occurs a few weeks later. If AVB is not
properly treated during the second stage, then
the blockage might progress to complete AVB.73
The management of CHB includes the
administration of parenteral steroids, such as
dexamethasone or betamethasone, with good
results. The intravenous administration of IgG
is also therapeutically successful.74,75 In the
case of complete AVB, the newborn would
require pacemaker implantation; however,
some babies may develop dilated cardiomyopa-
thy, and cardiac transplantation is the last
alternative to preserve the life of the neonate.56
Although CHB has been associated with signif-
icant morbidity and mortality, the survival rate
after 3 years is approximately 80%. When a
child with CHB becomes an adult, their CHB
history should be considered for managing
associated comorbidities.49,76 Concerning
maternal treatment during pregnancy, the
administration of hydroxychloroquine together
with a low dose of prednisone might exert pro-
tective effects.77 Other miscellaneous manifes-
tations of NL include hepatobiliary damage,
which can be associated with jaundice,
cholestatic hepatitis, and occasional thrombo-
cytopenia; anemia; hyperbilirubinemia; and
elevated transaminase levels. The hepatic dys-
function occurs in utero or appears shortly
after birth, and clinical and biochemical
parameters typically return to normal after
approximately eight weeks. Hemocytopenia
has also been reported in 10% of NL cases,
among which neutropenia and/or transitory
lymphopenia are frequent.29,78,79 Other rare
manifestations of NL occur in the central nerv-
ous system (CNS), including seizures, CNS
bleeding, or myelopathy.80-83
Conclusions
Lupus is a common disease in women of
reproductive age. Thus, it is important to con-
sider the possibility of neonatal syndromes
induced through ANA maternal autoantibod-
ies, including NL with or without CHB. As NL
with CHB must be detected prenatally, ade-
quate clinical, serological, and echocardio-
graphic screening must be performed in all
pregnant women with lupus or Sjögren’s syn-
drome. After the pregnancy is resolved, sys-
tematic postnatal maternal tracking must be
performed to determine the likelihood of NL in
subsequent pregnancies.84-87 Moreover, this
review acknowledges those who have per-
formed studies on NL, particularly Tom
Provost, who recently passed away. Indeed, his
original contribution to these studies triggered
a cascade of sophisticated research, revealing
the cellular and molecular mechanisms under-
lying the pathogenic role of maternal anti-
Ro/la antibodies in the induction of NL
pathologies.
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